Dr Susana Banerjee On Current Treatments And The Latest Advances In Ovarian Cancer

Dr Susana Banerjee on current treatments and the latest advances in ovarian cancer

Ovacome - the ovarian cancer charity

New approaches to ovarian cancer treatment - Prof Susana Banerjee (Part 1 of 2)

Imperial College London

Interview with Dr Susana Banerjee

Ovacome - the ovarian cancer charity

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Latest updates in low grade serous ovarian cancer treatment and research

Ovacome - the ovarian cancer charity

Drug combination shows promise in treatment-resistant advanced ovarian cancer

SOLO1-The 5-year Follow Up Data with Dr. Susana Banerjee

SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer

Ovarian Cancer: through the eyes of... Dr Susana Banerjee, Consultant Medical Oncologist

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Introductory Remarks - Susana Banerjee, London

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023

Touch Medical Media

Maintenance Olaparib Following Platinum-Based Chemotherapy for Newly Diagnosed Ovarian Cancer

PARP Therapies for Ovarian Cancer #SGOatASCO

Society of Gynecologic Oncology

New Data at the American Society of Clinical Oncology (ASCO) Addressing Rare Form of Ovarian Cancer

HPR

SOLO1 trial of maintenance olaparib in advanced ovarian cancer | Susana Banerjee

Medicine Matters oncology

Acetylsalicylic acid added to atezolizumab bevacizumab combo does not improve efficacy in ovaria...

Is Advance Ovarian Cancer Untreatable | Max Healthcare

Dr. Coleman on Advances Made in Ovarian Cancer Treatment

Weekly Paclitaxel Plus Bevacizumab for Relapsed Ovarian Sex Cord Tumors